-
公开(公告)号：EP2847199B1
公开(公告)日：2017-10-25
申请号：EP13787989.6
申请日：2013-05-03
发明人： SELNICK, Harold, G. , LI, Wenping , HOSTETLER, Eric , LIU, Kun , MCEACHERN, Ernest, J. , ZHOU, Yuanxi , WEI, Zhongyong , MU, Changwei , WANG, Yaode , CHANG, Jiang
IPC分类号： C07D513/04 , C07H9/06 , A61K31/429 , A61P25/00
CPC分类号： C07D513/04 , C07B59/005 , C07B2200/05 , C07H9/06
-
公开(公告)号：EP2847199A1
公开(公告)日：2015-03-18
申请号：EP13787989.6
申请日：2013-05-03
发明人： SELNICK, Harold, G. , LI, Wenping , HOSTETLER, Eric , LIU, Kun , MCEACHERN, Ernest, J. , ZHOU, Yuanxi , WEI, Zhongyong , MU, Changwei , WANG, Yaode , CHANG, Jiang
IPC分类号： C07D513/04
CPC分类号： C07D513/04 , C07B59/005 , C07B2200/05 , C07H9/06
摘要： The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.
摘要翻译： 本发明涉及包含这些化合物的化合物和药物制剂，其可用作O-联N-乙酰氨基葡糖苷酶（O-GlcNAcase）抑制剂，并因此可用于治疗某些病症如阿尔茨海默氏病，包括减少NFT和/ 或超磷酸化的tau。 本发明还涉及这些化合物作为O-GlcNAcase成像剂的用途。
-
3.发明公开
公开(公告)号：EP2528603A1
公开(公告)日：2012-12-05
申请号：EP11737514.7
申请日：2011-01-25
发明人： CHOBANIAN, Harry , LIN, Linus, S. , LIU, Ping , CHOIDA, Marc, D. , DEVITA, Robert, J. , NARGRUND, Ravi, P. , GUO, Yan , HAMILL, Terence , LI, Wenping , HENZE, Darrell, A.
IPC分类号： A61K31/42
CPC分类号： A61K31/422 , A61K31/4178
摘要： The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.
-
4.发明授权IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS 有权咪唑衍生物可用作FAAH调节剂和FAAH成像剂
公开(公告)号：EP2403338B1
公开(公告)日：2017-07-26
申请号：EP10749107.8
申请日：2010-02-22
发明人： LIU, Ping , DEVITA, Robert, J. , LIN, Linus, S. , CHIODA, Marc, D. , HAMILL, Terence, G. , LI, Wenping
IPC分类号： C07D401/14 , C07D413/14 , C07D401/12 , C07D413/10 , A61K31/415
CPC分类号： C07D401/12 , C07D401/14 , C07D413/10 , C07D413/14
-
5.发明公开IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS 有权咪唑衍生物AS FAAH调制器和AS FAAH造影剂
公开(公告)号：EP2403338A1
公开(公告)日：2012-01-11
申请号：EP10749107.8
申请日：2010-02-22
发明人： LIU, Ping , DEVITA, Robert, J. , LIN, Linus, S. , CHIODA, Marc, D. , HAMILL, Terence, G. , LI, Wenping
IPC分类号： A01N43/50 , A01N43/52 , A61K31/415
CPC分类号： C07D401/12 , C07D401/14 , C07D413/10 , C07D413/14
摘要： The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
